Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No. FDA-2015-E-2079]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice; correction.

# SUMMARY:

                        The Food and Drug Administration (FDA or the Agency) published a notice in the                         **Federal Register**                         of February 12, 2018, for the determination of the regulatory review period for the animal drug BRAVECTO. In accordance with the Court's order in                         *Nissan Chemical Corp., et al.*                         v.                         *FDA, et al.,*                         No. 22-01598 (D.D.C), this document revises the                         **SUPPLEMENTARY INFORMATION**                         section of that notice by adjusting the start date of the testing phase for BRAVECTO. This notice supersedes the June 11, 2021,                         **Federal Register**                         document revising the February 12, 2018, notice.                    

# FOR FURTHER INFORMATION CONTACT:

Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6250, Silver Spring, MD 20993, 301-796-3600.

# SUPPLEMENTARY INFORMATION:

                    In the                     **Federal Register**                     of February 12, 2018 (83 FR 6033), in FR Doc. 2018-02761, in the first column, the first two paragraphs under the section “II. Determination of Regulatory Review Period,” the following revision is made on page 6034:                

FDA has determined that the applicable regulatory review period for BRAVECTO is 1,548 days. Of this time, 1,510 days occurred during the testing phase of the regulatory review period, while 38 days occurred during the approval phase. These periods of time were derived from the following dates:

                    1.                     *The date an exemption under section 512(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360b(j)) became effective:*                     February 19, 2010. Pursuant to the Court's order in                     *Nissan Chemical Corp., et al.*                     v.                     *FDA, et al.,*                     No. 22-01598 (D.D.C), the start date of the testing phase for BRAVECTO was February 19, 2010.                

Dated: September 19, 2024.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2024-21841 Filed 9-23-24; 8:45 am]

BILLING CODE 4164-01-P